Arcotatug tavatecan improves progression-free survival in CLDN18.2-positive advanced gastric cancer

Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan
Arcotatug tavatecan improves progression-free survival in CLDN18.2-positive advanced gastric cancer ( Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan )
26 Oct 2026

Zanidatamab plus chemotherapy improves overall survival in HER2-positive advanced gastroesophageal cancer

Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan
Zanidatamab plus chemotherapy improves overall survival in HER2-positive advanced gastroesophageal cancer ( Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan )
26 Oct 2026

Omega-3 EPA improves overall survival after colorectal cancer liver metastasis resection

Prof Mark Hull - Leeds University, Leeds, UK
Omega-3 EPA improves overall survival after colorectal cancer liver metastasis resection ( Prof Mark Hull - Leeds University, Leeds, UK )
26 Oct 2026

Reduced dosing frequency of immune checkpoint inhibitors raises survival concerns in advanced cancer

Dr Gwenaëlle Gravis - Institut Paoli-Calmettes, Marseille, France
Reduced dosing frequency of immune checkpoint inhibitors raises survival concerns in advanced cancer ( Dr Gwenaëlle Gravis - Institut Paoli-Calmettes, Marseille, France )
26 Oct 2026

ESMO 2026: Highlights and analysis

Prof Bishal Gyawali - Queen's University, Kingston, Canada
ESMO 2026: Highlights and analysis ( Prof Bishal Gyawali - Queen's University, Kingston, Canada )
26 Oct 2026

Dostarlimab achieves durable complete clinical responses in dMMR/MSI-H locally advanced rectal cancer

Dr Meredith Pelster - Sarah Cannon Research Institute, Nashville, USA
Dostarlimab achieves durable complete clinical responses in dMMR/MSI-H locally advanced rectal cancer ( Dr Meredith Pelster - Sarah Cannon Research Institute, Nashville, USA )
26 Oct 2026

UEG 2026: Improving early detection of colorectal cancer

Mr Yegor Tryliskyy, Dr Violaine Randrian, Dr Giulio Antonelli and Deepa Gandhi
UEG 2026: Improving early detection of colorectal cancer ( Mr Yegor Tryliskyy, Dr Violaine Randrian, Dr Giulio Antonelli and Deepa Gandhi )
21 Oct 2026

Adagrasib plus cetuximab shows activity but does not improve survival in KRAS G12C-mutated metastatic colorectal cancer

Dr Josep Tabernero - Vall d'Hebron Institute of Oncology, Barcelona, Spain
Adagrasib plus cetuximab shows activity but does not improve survival in KRAS G12C-mutated metastatic colorectal cancer ( Dr Josep Tabernero - Vall d'Hebron Institute of Oncology, Barcelona, Spain )
13 Jul 2026

ctDNA MRD status predicts survival and adjuvant chemo benefit in resected colorectal liver metastas

Dr Kozo Kataoka - Hyogo Medical University, Nishinomiya, Japan
ctDNA MRD status predicts survival and adjuvant chemo benefit in resected colorectal liver metastas ( Dr Kozo Kataoka - Hyogo Medical University, Nishinomiya, Japan )
6 Jul 2026

Early ctDNA clearance linked to improved outcomes in KRAS G12C-mutant colorectal cancer

Dr Filippo Pietrantonio - Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Early ctDNA clearance linked to improved outcomes in KRAS G12C-mutant colorectal cancer ( Dr Filippo Pietrantonio - Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy )
10 Jun 2026

ASCO 2026: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada
ASCO 2026: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )
1 Jun 2026

Velzatinib demonstrates broad activity across KIT mutations in advanced gastrointestinal stromal tumours

Dr Neeta Somaiah - The University of Texas MD Anderson Cancer Center, Houston, USA
Velzatinib demonstrates broad activity across KIT mutations in advanced gastrointestinal stromal tumours ( Dr Neeta Somaiah - The University of Texas MD Anderson Cancer Center, Houston, USA )
1 Jun 2026